Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 12, 2010, Pages 4351-4362

  Milkiewicz, Karen L ^a   Weinberg, Linda R ^a   Albom, Mark S ^a   Angeles, Thelma S ^a   Cheng, Mangeng ^a   Ghose, Arup K ^a   Roemmele, Renee C ^b   Theroff, Jay P ^a   Underiner, Ted L ^a   Zificsak, Craig A ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

^b CPRD Cephalon Inc   (United States)

Author keywords

Anaplastic lymphoma kinase; Kinase inhibitors

Indexed keywords

1 (2 CHLORO 3,6 DIFLUORO BENZYL) 7 [6 (4 METHYLPIPERAZIN PIPERAZIN 1 YL)PYRIDIN 3 YL] 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2 CHLORO 3,6 DIFLUORO BENZYL) 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2 CHLORO 3,6 DIFLUORO BENZYL) 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1 (2 CHLORO 5 TRIFLUOROMETHYL BENZYL) 7 [6 (4 METHYLPIPERAZIN 1 YL)PYRIDIN 3 YL] 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2 CHLORO 5 TRIFLUOROMETHYL BENZYL) 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2 CHLORO 5 TRIFLUOROMETHYL BENZYL) 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1 (2,5 DICHLORO BENZYL) 7 [6 (4 METHYL PIPERAZIN 1 YL)PYRIDIN 3 YL] 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2,5 DICHLORO BENZYL) 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2,5 DICHLORO BENZYL) 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1 (2,5 DIFLUORO BENZYL) 7 [6 (4 METHYL PIPERAZIN 1 YL)PYRIDIN 3 YL] 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2,5 DIFLUORO BENZYL) 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2,5 DIFLUORO BENZYL) 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1 (2,6 DICHLORO BENZYL) 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (2,6 DICHLORO BENZYL) 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1 (5 CHLORO 2 TRIFLUOROMETHYL BENZYL) 7 [6 (4 METHYLPIPERAZIN 1 YL)PYRIDIN 3 YL] 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (5 CHLORO 2 TRIFLUOROMETHYL BENZYL) 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 (5 CHLORO 2 TRIFLUOROMETHYL BENZYL) 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1 BENZYL 7 IODO 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZINE; 1 BENZYL 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; 1,2,3,4 TETRAHYDROPYRIDO[2,3 B]PYRAZINE; 4 [1 (5 CHLORO 2 (TRIFLUOROMETHYL)BENZYL) 1,2,3,4 TETRAHYDROPYRIDO[2,3 B]PYRAZIN 7 YL]BENZOIC ACID; 4 [1 (5 CHLORO 2 (TRIFLUOROMETHYL)BENZYL) 1,2,3,4 TETRAHYDROPYRIDO[2,3 B]PYRAZIN 7 YL]BENZOIC ACID ETHYL ESTER; 7 IODO 3,4 DIHYDRO 1H PYRIDO[2,3 B]PYRAZIN 2 ONE; [1 ((5 CHLORO 2 TRIFLUOROMETHYL)BENZYL) 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZIN 7 YL]PIPERIDIN 1 YL METHANONE; [4 (1 (2,5 DIFLUORO BENZYL) 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZIN 7 YL)PHENYL] (2 PYRROLIDIN 1 YLMETHYLPYRROLIDIN 1 YL)METHANONE; [4 (1 (2,6 DICHLORO BENZYL) 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZIN 7 YL)PHENYL] (2 PYRROLIDIN 1 YLMETHYLPYRROLIDIN 1 YL)METHANONE; [4 (1 BENZYL 1,2,3,4 TETRAHYDRO PYRIDO[2,3 B]PYRAZIN 7 YL)PHENYL] (2 PYRROLIDINYLMETHYL PYRROLIDIN 1 YL)METHANONE; ANAPLASTIC LYMPHOMA KINASE; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME REGULATION; IC 50; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; SYNTHESIS;

ANTINEOPLASTIC AGENTS; BINDING SITES; COMPUTER SIMULATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 77953322598     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.04.087     Document Type: Article

References (37)

1. Duyster J., Bai R., and Morris S.W. Oncogene 20 (2001) 5623
2. Armitage, J.O. et al., Cancer: Principles and Practice of Oncology, 6th edition, 2001, pp 2256-2316.
3. Kutok J.L., and Aster J.C. J. Clin. Oncol. 20 (2002) 3691
4. Falini B., Pulford K., Pucciarini A., Carbone A., De Wolf-Peeters C., Cordell J., Fizzotti M., Santucci A., Pelicci P., Pileri S., Campo E., Ott G., Delsol G., and Mason D.Y. Blood 94 (1999) 3509
5. Morris S.W. Br. J. Haematol. 113 (2001) 275
6. Kuefer M.U., Look A.T., Pulford K., Behm F.G., Pattengale P.K., Mason D.Y., and Morris S.W. Blood 90 (1997) 2901
7. Bai R., Dieter P., Peschel C., Morris S.W., and Duyster J. Mol. Cell Biol. 18 (1998) 6951
8. Bai R., Ouyang T., Miething C., Morris S.W., Peschel C., and Duyster J. Blood 96 (2000) 4319
9. Ergin M., Denning M.F., Izban K.F., Amin H.M., Martinez R.L., Saeed S., and Alkan S. Exp. Hematol. 29 (2001) 1082
10. Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione A., Majewski M., Xue L., Morris S.W., Wasik M.A., and Skorski T. Cancer Res. 61 (2001) 94
11. Turturro F., Arnold M.D., Frist A.Y., and Pulford K. Clin. Cancer Res. 8 (2002) 240
12. Lawrence B., Perez-Atayde A., Hibbard M.K., Rubin B.P., Cin P.D., Pinkus J.L., Pinkus G.S., Xiao S., Yi E.S., Fletcher C.D.M., and Fletcher J.A. Am. J. Pathol. 157 (2000) 377
13. Stoica G.E., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C., Caughey D.J., Wen D., Karavanov A., Riegel A.T., and Wellstein A. J. Biol. Chem. 276 (2001) 16772
14. Powers C., Aigner A., Stoica G.E., McDonnell K., and Wellstein A. J. Biol. Chem. 277 (2002) 14153
15. Mentlein R., and Held-Feindt J. J. Neurochem. 83 (2002) 747
16. Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., and Maris J.M. Nature 455 (2008) 930
17. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., and Mano H. Nature 448 (2007) 561
18. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C., Lindeman N., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M., and Jaenne P.A. Clin. Cancer Res. 14 (2008) 4275
19. Mosse Y.P., Wood A., and Maris J.M. Clin. Cancer Res. 15 (2009) 5609
20. Anand, N. K.; Blazey, C. M.; Bowles, O. J.; Bussenius, J.; Costanzo, S.; Curtis, J. K.; Dubenko, L.; Kennedy, A. R.; Khoury, R. G.; Kim, A. I.; Manalo, J. L.; Peto, C. J.; Rice, K. D.; Tsang, T. H. PCT Int. Appl. 2005, WO 2005009389 A2 20050203.
21. Li R., Xue L., Zhu T., Jiang Q., Cui X., Yan Z., McGee D., Wang J., Gantla V.R., Pickens J.C., McGrath D., Chucholowski A., Morris S.W., and Webb T.R. J. Med. Chem. 49 (2006) 1006
22. Leahy, J. W.; Lewis, G. L.; Nuss, J. M.; Ridgway, B. H.; Sangalang, J. C. PCT Int. Appl. 2005, WO 2005097765.
23. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N., Li L., Xia G., Steensma R., Chopiuk G., Wan Y., Ding P., Liu Y., Sun F., Schultz P.G., Gray N.lS., and Warmuth M. PNAS 104 (2007) 270
24. Cui, J. J.; Funk, Le, A.; Jia, L.; Kung, P; Meng, J. J.; Nambu, M. D.; Pairish, M. A.; Shen, H.; Tran-Dube, M. B. PCT Int. Appl. 2006, WO 2006021886.
25. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P., Nambu M.D., Los G., Bender S.L., Mroczkowski B., and Christensen J.G. Cancer Res. 67 (2007) 4408
26. Cui, J. J.; Bhumralkar, D.; Botrous, I.; Chu J. Y.; Funk, L. A; Hanau, C. E.; Harris, G. D., Jr,; Jia, L. PCT Int. Appl. 2004, WO 2004076412.
27. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., and Los G. Mol. Cancer Ther. 6 (2007) 3314. http://www.clinicaltrials.gov/ct2/show/NCT00932893 Clinical trial data: http://www.clinicaltrials.gov/ct2/show/NCT00932893
28. Ghose A.K., Herbertz T., Pippin D.A., Salvino J.M., and Mallamo J.P. J. Med. Chem. 51 (2008) 5149
29. A single DFG-in homology model was built from insulin like growth factor receptor (IGF1R) structures using the kinase domain (1116-1392) of ALK_human sequence (Swiss-Prot entry Q9UM73), and aminopyridine and constrained aminopyridine scaffolds were docked in it using an automated docking method to elucidate their binding modes (Figs. 3 and 4).
30. Carroll F.I., Lee J.R., Navarro H.A., Ma W., Brieaddy L.E., Abraham P., Damaj M.I., and Martin B.R. J. Med. Chem. 45 (2002) 4755
31. DaSettimo A., Biagi G., Primofiore G., Ferrarini P.L., and Livi O. Farmaco-Ed Sci. 33 (1978) 770 Note: the referenced procedure was followed with the exception of the use of Eaton's reagent rather than PPA
32. Takai K., Nitta K., and Utimoto K. J. Am. Chem. Soc. 108 (1986) 7408
33. Fabian M.A., Biggs W.H., Treiber D.lK., Atteridge C.E., Azimioara M.D., Benedetti M.lG., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. Nat. Biotechnol. 23 (2005) 329
34. Takemura H., Kotoku M., Yasutake M., and Shinmyozu T. J. Chem. Res. 12 (2004) 834
35. Gunby R.H., Ahmed S., Sottocornola R., Gasser M., Redaelli S., et al. J. Med. Chem. 49 (2006) 5759
36. Angeles T.S., Steffler C., Bartlett B.A., Hudkins R.L., Stephens R.M., Kaplan D.R., and Dionne C.A. Anal. Biochem. 236 (1996) 49
37. Rotin D., Margolis B., Mohammadi M., Daly R.J., Daum G., Li N., Fischer E.H., Burgess W.H., Ullrich A., and Schlessinger J. EMBO J. 11 (1992) 559